- Page 1 and 2:
Immunotherapy for Infectious Diseas
- Page 3 and 4:
In f e c t i o u s . D i s e a s e
- Page 5 and 6:
© 2002 Humana Press Inc. 999 River
- Page 7 and 8:
vi Preface I am grateful to all of
- Page 9 and 10:
viii Contents 11 Passive Immunother
- Page 11 and 12:
x Contributors BARBARA G. MATTHEWS,
- Page 14 and 15:
From: Immunotherapy for Infectious
- Page 16 and 17:
Humoral Immunity 5 Fig. 1. Humoral
- Page 18 and 19:
Humoral Immunity 7 Table 1 Properti
- Page 20 and 21:
Humoral Immunity 9 minal complement
- Page 22 and 23:
Humoral Immunity 11 ficity. In ligh
- Page 24 and 25:
Humoral Immunity 13 Fig. 7. VDJ joi
- Page 26 and 27:
Humoral Immunity 15 Fig. 9. Messeng
- Page 28 and 29:
Humoral Immunity 17 In contrast to
- Page 30 and 31:
Humoral Immunity 19 advantage to tr
- Page 32 and 33:
Humoral Immunity 21 32. Allman DM,
- Page 34 and 35:
Some Basic Cellular Immunology Prin
- Page 36 and 37:
Cellular Immunology Principles 25 i
- Page 38 and 39:
Cellular Immunology Principles 27 s
- Page 40 and 41:
Cellular Immunology Principles 29 d
- Page 42 and 43:
Cellular Immunology Principles 31 f
- Page 44 and 45:
Cellular Immunology Principles 33 F
- Page 46 and 47:
Cellular Immunology Principles 35 R
- Page 48 and 49:
Cellular Immunology Principles 37 1
- Page 50 and 51:
INTRODUCTION Immune Defense at Muco
- Page 52 and 53:
Immune Defense at Mucosal Surfaces
- Page 54 and 55:
Immune Defense at Mucosal Surfaces
- Page 56 and 57:
Immune Defense at Mucosal Surfaces
- Page 58 and 59:
Immune Defense at Mucosal Surfaces
- Page 60 and 61:
Immune Defense at Mucosal Surfaces
- Page 62 and 63:
Immune Defense at Mucosal Surfaces
- Page 64 and 65:
Immune Defense at Mucosal Surfaces
- Page 66 and 67:
Immune Defense at Mucosal Surfaces
- Page 68 and 69:
Immune Defense at Mucosal Surfaces
- Page 70 and 71:
Immune Defense at Mucosal Surfaces
- Page 72:
II Molecular Basis for Immunotherap
- Page 75 and 76:
64 Kunert and Katinger IMMUNOGLOBUL
- Page 77 and 78:
66 Fig. 2. Monomeric, dimeric, and
- Page 79 and 80:
68 Kunert and Katinger Fig. 4. Humo
- Page 81 and 82:
70 Kunert and Katinger remove prote
- Page 83 and 84:
72 Kunert and Katinger Fig. 6. Diff
- Page 85 and 86:
74 Kunert and Katinger persons of a
- Page 87 and 88:
76 Kunert and Katinger that so-call
- Page 89 and 90:
78 Kunert and Katinger whereas sele
- Page 91 and 92:
80 Kunert and Katinger Different pr
- Page 93 and 94:
82 Kunert and Katinger HUMAN/MOUSE
- Page 95 and 96:
84 Kunert and Katinger are expresse
- Page 97 and 98:
86 Kunert and Katinger missing meta
- Page 99 and 100:
88 Kunert and Katinger Fig. 8. Sche
- Page 101 and 102:
90 Kunert and Katinger include a se
- Page 103 and 104:
92 Kunert and Katinger 32. Lee S, e
- Page 105 and 106:
94 Kunert and Katinger 72. Abbs IC,
- Page 107 and 108: 96 Kunert and Katinger 117. Wright
- Page 110 and 111: From: Immunotherapy for Infectious
- Page 112 and 113: Dendritic Cells 101 several organis
- Page 114 and 115: Dendritic Cells 103 tion that infec
- Page 116 and 117: Dendritic Cells 105 chaperones such
- Page 118 and 119: Dendritic Cells 107 CD8� CTLs, th
- Page 120 and 121: Dendritic Cells 109 complete tumor
- Page 122 and 123: Dendritic Cells 111 19. Holland SM,
- Page 124 and 125: Dendritic Cells 113 mouse pneumonit
- Page 126 and 127: Dendritic Cells 115 dendritic cells
- Page 128 and 129: INTRODUCTION Cytokines, Cytokine An
- Page 130 and 131: Cytokines, Cytokine Antagonists, an
- Page 132 and 133: Cytokines, Cytokine Antagonists, an
- Page 134 and 135: Cytokines, Cytokine Antagonists, an
- Page 136 and 137: Cytokines, Cytokine Antagonists, an
- Page 138 and 139: Cytokines, Cytokine Antagonists, an
- Page 140 and 141: Principles of Vaccine Development F
- Page 142 and 143: Principles of Vaccine Development 1
- Page 144 and 145: Principles of Vaccine Development 1
- Page 146 and 147: Principles of Vaccine Development 1
- Page 148 and 149: Principles of Vaccine Development 1
- Page 150 and 151: Principles of Vaccine Development 1
- Page 152 and 153: Principles of Vaccine Development 1
- Page 154 and 155: Principles of Vaccine Development 1
- Page 156 and 157: Principles of Vaccine Development 1
- Page 160: III Immunotherapy for HIV Infection
- Page 163 and 164: 152 Fox Scope of the Epidemic World
- Page 165 and 166: 154 Fox receptor binding by the V3
- Page 167 and 168: 156 Fox plasma cells. Failure of th
- Page 169 and 170: 158 Fox Challenges of Therapeutic T
- Page 171 and 172: 160 Fox REFERENCES 1. UNAIDS. Repor
- Page 174 and 175: INTRODUCTION Immune Reconstitution
- Page 176 and 177: Immune Reconstitution with Antiretr
- Page 178 and 179: Immune Reconstitution with Antiretr
- Page 180 and 181: Immune Reconstitution with Antiretr
- Page 182 and 183: Immune Reconstitution with Antiretr
- Page 184 and 185: Immune Reconstitution with Antiretr
- Page 186 and 187: Immune Reconstitution with Antiretr
- Page 188 and 189: Immune Reconstitution with Antiretr
- Page 190: Immune Reconstitution with Antiretr
- Page 193 and 194: 182 Kalams model, immune control is
- Page 195 and 196: 184 Kalams complexed with HLA class
- Page 197 and 198: 186 Kalams caused by an increase in
- Page 199 and 200: 188 Kalams series of treatment inte
- Page 201 and 202: 190 Kalams Another promising approa
- Page 203 and 204: 192 Kalams 29. Brander C, Hartman K
- Page 205 and 206: 194 Kalams 66. Altfeld M, Rosenberg
- Page 207 and 208: 196 Kalams virus infection. Militar
- Page 210 and 211:
INTRODUCTION From: Immunotherapy fo
- Page 212 and 213:
Passive Immunotherapy for HIV Infec
- Page 214 and 215:
Passive Immunotherapy for HIV Infec
- Page 216 and 217:
Passive Immunotherapy for HIV Infec
- Page 218 and 219:
Passive Immunotherapy for HIV Infec
- Page 220 and 221:
Passive Immunotherapy for HIV Infec
- Page 222 and 223:
Passive Immunotherapy for HIV Infec
- Page 224 and 225:
Passive Immunotherapy for HIV Infec
- Page 226 and 227:
Passive Immunotherapy for HIV Infec
- Page 228 and 229:
Passive Immunotherapy for HIV Infec
- Page 230 and 231:
Passive Immunotherapy for HIV Infec
- Page 232 and 233:
From: Immunotherapy for Infectious
- Page 234 and 235:
Host Cell-Directed Approaches 223 C
- Page 236 and 237:
Host Cell-Directed Approaches 225 s
- Page 238 and 239:
Host Cell-Directed Approaches 227 a
- Page 240 and 241:
Host Cell-Directed Approaches 229 t
- Page 242 and 243:
Host Cell-Directed Approaches 231 R
- Page 244 and 245:
Host Cell-Directed Approaches 233 4
- Page 246 and 247:
Host Cell-Directed Approaches 235 8
- Page 248 and 249:
INTRODUCTION From: Immunotherapy fo
- Page 250 and 251:
Gene Therapy for HIV-1 Infection 23
- Page 252 and 253:
Gene Therapy for HIV-1 Infection 24
- Page 254 and 255:
Gene Therapy for HIV-1 Infection 24
- Page 256 and 257:
Gene Therapy for HIV-1 Infection 24
- Page 258 and 259:
Gene Therapy for HIV-1 Infection 24
- Page 260:
IV Immunotherapy for Infectious Dis
- Page 263 and 264:
252 Onorato and Pollard However, th
- Page 265 and 266:
254 Onorato and Pollard patients wi
- Page 267 and 268:
256 Onorato and Pollard Another imm
- Page 269 and 270:
258 Onorato and Pollard 26. Guidott
- Page 271 and 272:
260 Sili, Heslop, and Rooney Fig. 1
- Page 273 and 274:
262 Sili, Heslop, and Rooney Fig. 2
- Page 275 and 276:
264 Sili, Heslop, and Rooney immuno
- Page 277 and 278:
266 Sili, Heslop, and Rooney Fig. 3
- Page 279 and 280:
268 Sili, Heslop, and Rooney Human
- Page 281 and 282:
270 Sili, Heslop, and Rooney CONCLU
- Page 283 and 284:
272 Sili, Heslop, and Rooney 32. Ba
- Page 285 and 286:
274 Sili, Heslop, and Rooney 73. va
- Page 287 and 288:
276 Donta no controlled clinical tr
- Page 289 and 290:
278 Donta antibody preparation (HA-
- Page 291 and 292:
280 Donta 16. Salcedo J, Keates S,
- Page 294 and 295:
INTRODUCTION From: Immunotherapy fo
- Page 296 and 297:
Tuberculosis and Other Mycobacteria
- Page 298 and 299:
Tuberculosis and Other Mycobacteria
- Page 300 and 301:
Tuberculosis and Other Mycobacteria
- Page 302 and 303:
Tuberculosis and Other Mycobacteria
- Page 304 and 305:
Tuberculosis and Other Mycobacteria
- Page 306 and 307:
Tuberculosis and Other Mycobacteria
- Page 308 and 309:
Tuberculosis and Other Mycobacteria
- Page 310 and 311:
Tuberculosis and Other Mycobacteria
- Page 312 and 313:
Tuberculosis and Other Mycobacteria
- Page 314 and 315:
From: Immunotherapy for Infectious
- Page 316 and 317:
Fungal Infections 305 Table 2 Categ
- Page 318 and 319:
Fungal Infections 307 rapid bone ma
- Page 320 and 321:
Fungal Infections 309 has activity
- Page 322 and 323:
311 Table 4 Case Reports of Unusual
- Page 324 and 325:
Fungal Infections 313 randomized co
- Page 326 and 327:
Fungal Infections 315 the administr
- Page 328 and 329:
Fungal Infections 317 modalities in
- Page 330 and 331:
Fungal Infections 319 35. Vecchiare
- Page 332 and 333:
Fungal Infections 321 74. Han Y, Cu
- Page 334 and 335:
Index 323 A ADCC, see Antibody-depe
- Page 336 and 337:
Index 325 immunotherapy clinical tr
- Page 338 and 339:
Index 327 function, 32, 33, 182-185
- Page 340 and 341:
Index 329 secretory immunoglobulin
- Page 342 and 343:
Index 331 dendritic cell response,